Ipsos Healthcare launches haematology diagnostics monitor
The Haematological Malignancies MDx Monitor is the latest addition to the Ipsos Global Oncology Centre of Excellence. It measures and tracks the usage of companion diagnostics and other tests across a range of leukaemias and lymphomas, using a panel of haematologists, medical oncologists and haematological oncologists, alongside a separate panel of (haemato-) pathologists, the study captures both perceptual and behavioural data on cytogenetics, mutational analysis, flow cytometry, minimal residual disease monitoring and other emerging molecular markers.
Panel members complete a perceptual questionnaire as well as a number of actual, anonymised patient record forms and tissue/ sample forms.
The monitor is based on the same overall approach that has been applied to the solid tumours Oncology MDx Monitor launched in 2012, but has been modified to account for the different testing paradigms in liquid tumours.
It currently covers the US but will be rolled out in the EU5 (France, Germany, Italy, Spain, UK) and other markets shortly.
We hope you enjoyed this article.
Research Live is published by MRS.
The Market Research Society (MRS) exists to promote and protect the research sector, showcasing how research delivers impact for businesses and government.
Members of MRS enjoy many benefits including tailoured policy guidance, discounts on training and conferences, and access to member-only content.
For example, there's an archive of winning case studies from over a decade of MRS Awards.
Find out more about the benefits of joining MRS here.
0 Comments